(Q38124014)

29 August 2017

Optimizing the use of anticoagulants (heparins and oral anticoagulants) in the elderly (English)

1 reference

29 August 2017

1 reference

3

Pascale Gaussem

1 reference

29 August 2017

Virginie Siguret

1

1 reference

PubMed ID

23884865

29 August 2017

Isabelle Gouin-Thibault

series ordinal

2

1 reference

PubMed ID

23884865

29 August 2017

Eric Pautas

series ordinal

4

1 reference

29 August 2017

1 September 2013

1 reference

29 August 2017

1 reference

29 August 2017

30

1 reference

29 August 2017

9

1 reference

29 August 2017

687-699

1 reference

https://scigraph.springernature.com/pub.10.1007/s40266-013-0101-0

29 August 2017

0 references

cites work

Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE)

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Bleeding risks of antithrombotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Estimating the prevalence of renal insufficiency in seniors requiring long-term care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Serum creatinine is an inadequate screening test for renal failure in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

A new equation to estimate glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Epidemiology and prognostic significance of chronic kidney disease in the elderly--the Three-City prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Apixaban versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Apixaban in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Is Modification of Diet in Renal Disease formula similar to Cockcroft-Gault formula to assess renal function in elderly hospitalized patients treated with low-molecular-weight heparin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Glomerular filtration rate estimated by Cockcroft-Gault formula better predicts anti-Xa levels than modification of the diet in renal disease equation in older patients with prophylactic enoxaparin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Fondaparinux - data on efficacy and safety in special situations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium : a prospective, open-label, observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

How and when to monitor a patient treated with low molecular weight heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

A need for evidence-based clinical practice guidelines for the use of heparins in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Ger

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

The use of oral anticoagulants (warfarin) in older people. American Geriatrics Society guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Underuse of oral anticoagulants in atrial fibrillation: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Oral anticoagulants in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Improving anticoagulation control in hospitalized elderly patients on warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

INR targets and site-level anticoagulation control: results from the Veterans AffaiRs Study to Improve Anticoagulation (VARIA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Safety of anticoagulation therapy in well-informed older patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Death and disability from warfarin-associated intracranial and extracranial hemorrhages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

Acute Coronary Care in the Elderly, Part I

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0101-0

The frequency of prescription of P-glycoprotein-affecting drugs in atrial fibrillation

21 January 2018

1 reference

12 December 2020

Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation.

1 reference

12 December 2020

Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy

1 reference

12 December 2020

Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study.

1 reference

12 December 2020

Bleeding Risk in Very Old Patients on Vitamin K Antagonist Treatment

1 reference

12 December 2020

Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study

1 reference

12 December 2020

Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin)

1 reference

12 December 2020

Effect of warfarin nonadherence on control of the International Normalized Ratio.

1 reference

12 December 2020

Newly identified events in the RE-LY trial

1 reference

12 December 2020

Venous thromboembolism in nonagenarians. Findings from the RIETE Registry.

1 reference

12 December 2020

New anticoagulant drugs among elderly patients is caution necessary?: Comment on "The use of dabigatran in elderly patients"

1 reference

12 December 2020

The association of age with dosage requirement for warfarin

1 reference

12 December 2020

Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study

1 reference

12 December 2020

Comparison of bleeding complications and one-year survival of low molecular weight heparin versus unfractioned heparin for acute myocardial infarction in elderly patients. The FAST-MI registry

1 reference

12 December 2020

Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study

1 reference

12 December 2020

Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin

1 reference

12 December 2020

Venous thromboembolism in the elderly. A community-based perspective

1 reference

12 December 2020

Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators

1 reference

12 December 2020

Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE).

1 reference

12 December 2020

Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

1 reference

12 December 2020

Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran

1 reference

12 December 2020

Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: The Innohep® in Renal Insufficiency Study (IRIS)

1 reference

12 December 2020

Reversal of overanticoagulation in very elderly hospitalized patients with an INR above 5.0: 24-hour INR response after vitamin K administration

1 reference

12 December 2020

Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days

1 reference

12 December 2020

Excess antivitamin K in elderly hospitalised patients aged over 70. A one-year prospective survey

1 reference

12 December 2020

Venous thromboembolism according to age: the impact of an aging population.

1 reference

12 December 2020

No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: the IRIS substudy

1 reference

12 December 2020

Aging and heparin-related bleeding

1 reference

12 December 2020

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

1 reference

12 December 2020

10.1007/S40266-013-0101-0

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

23884865